

## Calithera Biosciences to Present Data at the 55<sup>th</sup> American Society for Hematology Annual Meeting and the 2013 San Antonio Breast Cancer Symposium

November 26, 2013 5:08 PM ET

### *Preclinical Results for CB-839 Demonstrate Anti-Tumor Activity in Hematologic Malignancies and Triple-Negative Breast Cancer*

**South San Francisco, CA; November 26, 2013** – Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at two upcoming scientific conferences. CB-839 is a potent and selective orally bioavailable glutaminase inhibitor that blocks the growth and survival of many different types of cancer cells by interfering with their metabolism of glutamine. Calithera plans to advance CB-839 into Phase 1 clinical trials in patients with advanced solid and hematological tumors in early 2014.

At the 55<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, being held December 7-10, 2013, Calithera will present data from *in vitro* and *in vivo* studies evaluating CB-839 against diverse hematologic malignancies.

- Poster Presentation: *Antitumor Activity of the Glutaminase Inhibitor CB-839 in Hematological Malignancies*
- Monday, December 9, 2013, 6:00 pm - 8:00 pm
- Session 802: Chemical Biology and Experimental Therapeutics
- Abstract #4226

During the 2013 San Antonio Breast Cancer Symposium, being held December 10-14, 2013, Calithera will present *in vitro* and *in vivo* data on the anti-tumor activity of CB-839 in triplenegative breast cancer models.

- Poster Presentation: *Antitumor Activity of the Glutaminase Inhibitor, CB-839, in Triple-Negative Breast Cancer*
- Thursday, December 12, 2013, 7:30 am – 9:00 am
- Poster Session 2: Tumor Cell and Molecular biology
- Abstract # P2-09-03

“The presentations at ASH and the SABC Symposium will allow us to share the promising preclinical evidence of antitumor activity for CB-839 in both liquid and solid tumor types where glutaminase expression is believed to be a driver of tumor growth,” said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera Biosciences. “Based on these results, we are looking forward to initiating clinical studies for CB-839 early next year.”

### **About Calithera Biosciences**

Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival. The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development. The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics. Calithera’s lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing. Calithera Biosciences is a privately held company located in South San Francisco, CA. For more information, please visit [www.calithera.com](http://www.calithera.com).

###

#### *Contacts:*

Susan M. Molineaux, PhD  
President and CEO  
Calithera Biosciences

[info@calithera.com](mailto:info@calithera.com)

BCC Partners

Karen L. Bergman or

Michelle Corral

650.575.1509

415.794.8662